Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTD Induction Followed by MPT Maintenance in Non-Transplant Multiple Myeloma
NCT00320476Phase 2Completed
- Start
- Apr 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM). Primary endpoint: Response rate of VTD induction Therapy. Started Apr 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00320476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320476.